Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 718
- Registration Number
- NCT00170755
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.
- Conditions
- Dyspepsia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00171470
- Locations
- 🇺🇸
http://www.novartisclinicaltrials.com/etrials/DiseaseID21/Dyspepsia-clinical-trials.go, East Hanover, New Jersey, United States
The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.
- Conditions
- DyspepsiaHeartburn
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-10-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00171457
- Locations
- 🇺🇸
Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
- Conditions
- Kidney Transplantation
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Novartis
- Registration Number
- NCT00170885
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients
- Conditions
- Liver Transplant
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 47
- Registration Number
- NCT00171743
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 252
- Registration Number
- NCT00171171
- Locations
- 🇸🇾
Novartis Investigative Site, Damascus, Syrian Arab Republic
🇱🇧Ali Taher, Beirut, Lebanon
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
- Conditions
- Recurrent Genital Herpes
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1461
- Registration Number
- NCT00171990
- Locations
- 🇦🇺
Novartis Investigative Site, North Ryde, Australia
Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
- Conditions
- Glioblastoma
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00171938
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 400
- Registration Number
- NCT00171184
- Locations
- 🇺🇸
Scott Department of Urology Baylor College of Medicine, Houston, Texas, United States
A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery
- Conditions
- Cataract Surgery
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 62
- Registration Number
- NCT00170729